Tag: opzelura

All

Incyte’s sNDA for ruxolitinib cream in children ages 2–11 now faces a new action date to allow additional data review.

Research suggests patients using medical weight loss drugs are increasingly seeking treatments for facial volume loss and other appearance changes.